Insider · CIK 0001749623
Mark C. McKenna
directorother
Files at SYRE (Spyre Therapeutics, Inc.), BBOT (BridgeBio Oncology Therapeutics, Inc.), APGE (Apogee Therapeutics, Inc.). First filing Dec 16, 2024, latest Dec 16, 2024.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 0
$991k bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 48Moderate | APGEbuy Apogee Therapeutics, Inc. | $991k 20,000 shares | - | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Common Stock | -20,000 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -150,000 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,370 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -14,461 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,657 | - | - | 0 | 39 d ago |
| Aug 11, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | MOption exercise Common Stock | +30,000 | - | - | 30,000 | Aug 11, 2025 |
| Aug 11, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | MOption exercise Class B ordinary sharesderivative | -30,000 | $0.00 | $0 | 0 | Aug 11, 2025 |
| Jun 17, 2025 | APGE Apogee Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +14,461 | $0.00 | $0 | 14,461 | Jun 20, 2025 |
| May 29, 2025 | SYRE Spyre Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jun 2, 2025 |
| Dec 12, 2024 | APGE Apogee Therapeutics, Inc. | POpen-market purchase Common Stock | +7,500 | $49.02 | $368k | 7,500 | Dec 16, 2024 |
| Dec 12, 2024 | APGE Apogee Therapeutics, Inc. | POpen-market purchase Common Stock | +12,500 | $49.85 | $623k | 20,000 | Dec 16, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.